Peripheral parenteral nutrition (PPN) is increasingly considered as an alternative to central parenteral nutrition (CPN) given the higher cost and more frequent clinical complications associated with the latter. However, the assessment of potential risks and benefits of PPN in critically ill pediatric canine patients has not been extensively performed. In this study, we aimed to explore the effect of short-term, hypocaloric PPN on weight loss, length of hospital stay, the incidence of complications, adverse effects, and mortality in critically ill pediatric canine patients. Between August 2015 and August 2018, a total of 59 critically ill pediatric canine patients aged from 1 to 6 months admitted at the Veterinary Sciences Research Institute of the Autonomous University of Baja California were included in this non-randomized clinical trial. Canine pediatric patients were initially allocated to 3 groups: 11 in group 1 receiving parenteral nutrition (PN) supplementation equivalent to 40% of the resting energy requirement (RER), 12 in group 2 receiving supplementation of 50% of the RER, and 36 in group 3 receiving no PN supplementation. After establishing that there was no significant difference between 40 and 50% of PN supplementation, these groups were not separated for downstream analysis. Similar lengths of hospital stays were noted among study subjects who received PN supplementation and those who did not (4.3 ± 1.5 vs. 5.0 ± 1.5, days, p = 0.097). No metabolic-, sepsis- or phlebitis-related complications were observed in any animal in the PPN supplemented group. Higher mortality (19.4% vs. 0%, p = 0.036), and a greater percentage of weight loss (9.24% vs. 0%, p < 0.001) were observed in patients who received no supplementation. Even though short-term, hypocaloric PPN did not reduce the length of hospital stay, it was associated with lower mortality and resulted in mitigation of weight loss. In contrast to previous studies evaluating central and peripheral parenteral nutrition protocols, we observed a lower frequency of metabolic, septic, and phlebitis complications using a 40–50% parenteral nutrition treatment. The parenteral nutrition therapeutic intervention used in our study may reduce PN-related adverse effects and promote a favorable disease outcome in critically ill canine patients. Larger studies will be needed to confirm these observations.

中文翻译：

---

短期外周肠外营养对危重病犬儿患者治疗结果和死亡率的影响

外周肠外营养 (PPN) 越来越多地被认为是中央肠外营养 (CPN) 的替代方案，因为后者成本更高，而且临床并发症也更频繁。然而，尚未广泛评估 PPN 在危重儿科犬类患者中的潜在风险和益处。在本研究中，我们旨在探讨短期、低热量 PPN 对危重病儿科犬患者的体重减轻、住院时间、并发症发生率、不良反应和死亡率的影响。2015 年 8 月至 2018 年 8 月期间，本次非随机临床试验共纳入了 59 名在下加利福尼亚自治大学兽医科学研究所收治的 1 至 6 个月大儿科犬危重症患者。犬儿科患者最初被分为 3 组：第 1 组 11 名接受相当于静息能量需求 (RER) 40% 的肠外营养 (PN) 补充剂，第 2 组中 12 名接受相当于 RER 50% 的补充剂，36 名接受肠外营养 (PN) 补充第 3 组未接受 PN 补充。在确定 40% 和 50% 的 PN 补充之间没有显着差异后，这些组没有被分开进行下游分析。在接受 PN 补充和未补充的研究对象中注意到类似的住院时间长度（4.3 ± 1.5 vs. 5.0 ± 1.5，天，p = 0.097）。在 PPN 补充组的任何动物中均未观察到与代谢、败血症或静脉炎相关的并发症。更高的死亡率（19.4% 对 0%，p = 0.036）和更大的体重减轻百分比（9.24% 对 0%，p < 0。001) 在未接受补充的患者中观察到。尽管短期低热量 PPN 并没有减少住院时间，但它与较低的死亡率相关并导致减轻体重减轻。与之前评估中枢和外周肠外营养方案的研究相比，我们观察到使用 40-50% 的肠外营养治疗的代谢、败血症和静脉炎并发症发生率较低。我们研究中使用的肠外营养治疗干预可能会减少与 PN 相关的不良反应，并促进危重病犬患者的良好疾病结果。需要更大规模的研究来证实这些观察结果。它与较低的死亡率有关，并导致减轻体重减轻。与之前评估中枢和外周肠外营养方案的研究相比，我们观察到使用 40-50% 的肠外营养治疗的代谢、败血症和静脉炎并发症发生率较低。我们研究中使用的肠外营养治疗干预可能会减少与 PN 相关的不良反应，并促进危重病犬患者的良好疾病结果。需要更大规模的研究来证实这些观察结果。它与较低的死亡率有关，并导致减轻体重减轻。与之前评估中枢和外周肠外营养方案的研究相比，我们观察到使用 40-50% 的肠外营养治疗的代谢、败血症和静脉炎并发症发生率较低。我们研究中使用的肠外营养治疗干预可能会减少与 PN 相关的不良反应，并促进危重病犬患者的良好疾病结果。需要更大规模的研究来证实这些观察结果。我们研究中使用的肠外营养治疗干预可能会减少与 PN 相关的不良反应，并促进危重病犬患者的良好疾病结果。需要更大规模的研究来证实这些观察结果。我们研究中使用的肠外营养治疗干预可能会减少与 PN 相关的不良反应，并促进危重病犬患者的良好疾病结果。需要更大规模的研究来证实这些观察结果。